SAN FRANCISCO, CALIFORNIA--(Marketwired - July 5, 2017) - venBio Global Strategic Fund, L.P. ("venBio") announced today that as a result of the closing on March 14, 2017 of a public offering (the "Offering") of 22,300,000 common shares ("Common Shares") by Aurinia Pharmaceuticals Inc. (the "Company"), the number of Common Shares held by venBio decreased to less than 10% of the issued and outstanding Common Shares.